Abstract
Obesity is a chronic, progressive and relapsing disease, characterised by the presence of abnormal or excess adiposity that impairs health and social wellbeing. It is associated with obesity-related disease complications, health inequalities and premature death. Clinical evaluation of obesity requires a thorough history and examination. Assessment should focus not only on anthropometric measurements, but also on the mental, metabolic, mechanical and monetary impact of adiposity, including multiple health conditions. Increased awareness and knowledge will help reduce weight stigma and biases. A focused non-judgemental assessment will help guide further investigations, timely referral and management.
KEYWORDS: obesity, overweight, assessment of obesity, weight stigma, BMI
Introduction
Obesity is a major public health challenge that contributes directly and indirectly to multiple health conditions, health inequalities and premature death. Since 1975, obesity has tripled worldwide.1 The UK has the highest rates of obesity in Europe with most of the adult population (64%) now classed as overweight, of which 26% are classed as obese.2 Obesity-related disease complications include type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, chronic kidney disease, obstructive sleep apnoea (OSA), gastro-oesophageal reflux, osteoarthritis, metabolic-associated fatty liver disease, subfertility/infertility and cancer.3,4 Therefore, obesity prevention and care are crucial in terms of individual health as well as system resource impact and population health. Hence, it is imperative that all healthcare professionals can identify and accurately assess people who are overweight or obese. Here, we discuss key points regarding the evaluation and assessment of obesity.
Definition and classification
Obesity is a complex, relapsing chronic disease process and is defined by the World Health Organization as abnormal or excessive fat accumulation that presents a risk to health.5
Body mass index (BMI), calculated as weight in kilograms divided by height in metres squared, is universally used to define the degree of overweight or obesity (Table 1). A lower cut-off is used for certain ethnicities because they have higher visceral adiposity with increased predisposition to cardiometabolic disease.6
Table 1.
Classification using BMI
BMI in the general population (kg/m2) | BMI in certain ethnic groups (kg/m2)* | |
---|---|---|
Overweight | 25–29.9 | 23–27.4 |
Obesity Class 1 | 30 – 34.9 | 27.5–32.4 |
Obesity Class 2 | 35–39.9 | 32.5–37.4 |
Obesity Class 3 | >40 | >37.5 |
*South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean.
BMI = body mass index.
BMI is easy to measure, inexpensive and useful in population studies; however, it has limitations as a measurement tool for obesity because it does not necessarily correlate with body fat. It does not take into account other factors, such as gender, age, bone structure, muscle mass or fat distribution.7 Hence, there is a group of people classified as overweight or obese without overt cardiometabolic abnormalities who are said to have ‘metabolically healthy obesity’ (MHO).8 Although they are at a lower risk of obesity-related complications compared with individuals with metabolically unhealthy obesity (MUO), their risk is still higher compared with metabolically healthy lean people. Even among people with early T2DM and a normal BMI, substantial weight loss results in normal glucose tolerance, an observation that led to the hypothesis of a personal fat threshold (PFT). This appears to be independent of BMI.9
BMI does not take into account the complexity of obesity, hence the shift in defining obesity and the coining of the term ‘adiposity-based chronic disease’ (ABCD).10 There is a need to shift the focus toward improving patients' overall health rather than simply losing weight. Hence, current staging criteria consider risk factors, multiple health conditions, and quality of life to aid decision-making regarding treatment. The King's Obesity Staging Criteria (Table 2) comprise the following health domains: airways, BMI, cardiovascular disease, diabetes, economic complications, functional limitations, gonadal axis, health status (perceived),and body image.11
Table 2.
Modified King's Criteria for obesity scoring
Criteria | Stage 0 | Stage 1 | Stage 2 | Stage 3 |
---|---|---|---|---|
Normal health | At risk of disease | Established disease | Advanced disease | |
Airways | Normal | Snoring | Requires CPAP | Cor pulmonale |
Body mass index | <35 | 35–40 | 40–60 | >60 |
Cardiovascular | <10% risk | 10–20% risk | Heart disease | Heart failure |
Diabetes | Normal | Impaired fasting glycemia | Type 2 diabetes mellitus | Uncontrolled type 3 diabetes mellitus |
Economic | Normal | Expensive travel/clothes | Workplace discrimination | Unemployed because of obesity |
Functional | Can manage three flights of stairs | Manages one or two flights of stairs | Requires walking aids or wheelchairs | Housebound |
Gonadal | Normal | PCOS | Infertility | Sexual dysfunction |
Health perceived | Normal | Low mood or QoL | Depression or poor QoL | Severe depression |
Body image | Normal | Dislikes body | Body image dysphoria | Eating disorder with purging |
CPAP = continuous positive airway pressure; PCOS = polycystic ovarian syndrome; QoL = quality of life.
The Edmonton Obesity Staging System (EOSS) is a five-stage classification system that considers the presence of obesity-related risk factors, physical and psychological symptoms, and functional limitations as a result of obesity.12 This approach helps identify individuals with obesity who are at a greater mortality risk.13 These staging systems not only link to prognosis, but can also be practically used to stratify risk and obesity-related complications, which can be down-staged with treatment.11,12
However, there is a need for clinical and biological criteria for the diagnosis of obesity to be established to focus on the effects of obesity and help guide clinicians and policy makers.14
Initiating the conversation
Discussing weight should be done in a sensitive and respectful manner and permission to do so should be sought initially.15 Weight stigma has a negative impact on mental and physical health and needs to change across society.16 In healthcare settings, weight stigma is detrimental to health of people with obesity and all healthcare professionals have a responsibility to help with its eradication.17 We must explore our assumptions and biases about obesity and ensure that these are not relayed to the patient.18
The language used can have a profound effect on people with obesity, leading to stigma and discrimination, and it is vital to use inclusive and supportive language. Language Matters: Obesity is a set of evidence-based principles that encourages positive interactions and outcomes among healthcare professionals and individuals with obesity.18 Table 3 highlights quotes adopted from real conversations included in this document that provide guidance with regards to initiating the conversation.
Table 3.
Guidance on how to initiate a conversation around obesity with a patient
Avoid | Try instead |
---|---|
I'm sure the problems you've had are all related to your weight | Would you mind if we spoke about your weight? Where do you think you're at? |
You're a bit on the chunky side shall we say? | Some people with your symptoms find that losing a bit of weight and a little exercise can be useful. |
Ideally your BMI, which is your height in relation to your weight, should be somewhere between 18 and 25... between 30 and 35 you're considered clinically obese... from the measurements that you've had done today, you certainly fall into that category. | And as you said, your weight's crept up a bit... You said you'd like to lose some weight because you're feeling quite breathless... |
BMI = body mass index.
Assessing readiness to change
Although is important to assess the readiness to adopt change, eliciting behavioural change can be challenging.19 Helping people to change behaviour remains complex. Motivational Interviewing (MI) is an evidence-based psychological method designed to support change. The aim of MI is to promote a helpful conversation within an empathic and accepting environment that allows the person to consider their own motivations to change. People are frequently ambivalent about change in their own lives and can struggle to decide whether to make any changes, even when attending specialist obesity services. The traditional approach of placing pressure on people to change by persuasion through education and information often results in a negative effect, potentially increasing the desire not to change. MI in its guiding style recognises that, to help people change, we need their expertise and engagement, which can support change to happen. MI delivers a specific skill set within a series of tasks that is both relational (engaging) and directional in focusing on the language of change (Change Talk).20 Rollnick et al21 suggest using a specific style of practice to harness change for patients that requires a specific clinician's mindset (Spirit) in which:
you view your patient as a person first, patient second
you place high value on connecting well
you work with their strengths, not only their problems or deficits
you champion choice and believe that patients are capable of making wise decisions about their lives
you offer advice rather than impose it.
Clinical staff require initial training as well as ongoing coaching and supervision in the skills and strategies of MI to increase their competency in the method.
History and examination
A basic clinical assessment should be undertaken, which will help the treatment be tailored accordingly.22 Although changes leading to an ‘obesogenic’ environment have resulted in an increased prevalence of obesity, genetic factors have a significant role in determining body weight.23 Although the causes of obesity are discussed in detail elsewhere, it is worth thinking about whether the root cause of weight gain in the individual is because of increased intake, decreased metabolism, or reduced activity. Addressing the root cause will help tailor the management plan. The obesity system map can help highlight the systemic structure to the complex problem and, thus, can help address the barriers to effective management.24
History
History should also include the following points:
Onset of weight gain: early onset of obesity with dysmorphic features can point toward genetic causes25
Developmental delay and intellectual deficits: indicative of genetic causes of obesity
Menstrual irregularities can occur in polycystic ovarian syndrome (PCOS), Cushing's syndrome, hypothyroidism, menopause or even pregnancy
Presence of other medical conditions, such as T2DM, fatty liver disease, osteoarthritis, cardiovascular disease, OSA, cardiovascular disease, heart failure and cancer
History of cranial radiotherapy or surgery leading to hypothalamic disorders25
Family history of excess weight and other medical conditions
Drug history, including medication that can cause weight gain. These include antidepressants, antipsychotics, insulin, anti-epileptics, corticosteroids, even topical formulations25
Social history, including alcohol intake, socioeconomic background and ethnicity. Deprivation might make it more challenging to adopt a healthier lifestyle
Diet history, including speed of eating and eating environment. Eating disorders, mental health conditions and hypothalamic disorders can result in overeating. Autonomy in creating meals might not always be possible for all, such as for people in supported living
Allergies and intolerances
Physical activity and sleep. Insufficient sleep and circadian misalignment can contribute to weight gain.26 Modern working patterns and lifestyles, such as shift work and late-night screen time, result in sleep disruption and should be taken into consideration
History of weight-loss attempts, and lifestyle and treatment modalities used.
Genetic causes of obesity
Early onset of obesity and hyperphagia are very strong predictors of monogenic obesity if found together, or with a combination of other factors, such as a learning disability, syndromic features or central endocrine abnormalities, which suggest rare genetic causes.27,28 Rapidity of progression, increased severity and resistance to treatment can point toward genetic obesity. These characteristics observed in isolation can be seen in polygenic obesity, which is the most common form of obesity. This is covered in more detail in another article within this special issue.
Examination
For examination, we need to ensure that the examination equipment is appropriate for individuals with obesity, including the size of gowns, chairs available and even appropriate-sized blood pressure cuffs. The British Hypertension Society recommends a large cuff for people with obesity because, if used, a regular cuff can overestimate the blood pressure, thus leading to overdiagnosis of hypertension.29
Anthropometric measures
BMI is commonly used and easy to measure. In terms of BMI, sarcopenic obesity should be kept in mind. With age, muscle mass decreases and the combination of sarcopenia and obesity results in a high-risk geriatric syndrome in which there might be complications resulting from further weight loss.30
Apart from BMI, other measures can be used. Waist circumference (WC) measured with a tape around the waist midway between the bottom of the ribs and top of the pelvis (Fig 1) is a good measure of central adiposity. Waist to height ratio (WHtR) is calculated by dividing the WC by the height in the same units.19 Increased health risks are associated with a WHR of 0.5 to 0.59 and further increased risk if the ratio is >0.6. The target range is a ratio of <0.5; that is, the weight should be less than half the height. Although there are many indicators using WC to help assess central adiposity, WHtR appears to be a preferable indicator for the assessment of cardiovascular disease.31 The remainder of the examination should be focused on the effects of obesity, secondary causes, complications and multiple health conditions of obesity.
Fig 1.
Point at which waist circumference is measured.
Moderate weight loss (5–10%) can be beneficial but the overall target should be health improvement.32 Weight regain following weight loss is a complicated issue beyond patient motivation. There is a natural tendency for weight regain, which should be acknowledged because of mechanisms such as changes in appetite, resting energy expenditure and gut hormone secretion.33 Thus, not gaining weight can sometimes be an achievement and might be the goal in certain cases.
Complications, multiple health conditions and barriers
Complications, multiple health conditions and barriers to ongoing obesity management should be considered and have been categorised as the ‘4 Ms’ – Mental, Mechanical, Metabolic and Monetory.34 Mental refers to the complications and barriers related to mental health; mechanical refers to disorders related to excess body weight; metabolic refers to metabolic consequences, endocrine disorders such as PCOS, Cushing's syndrome, hypothyroidism, endocrine-related cancers; and monetary refers to the impact of obesity on income and other financial aspects. This approach will help address most of the issues and, thus, guide treatment. As mentioned previously, obesity scoring using the modified King's Obesity Staging Criteria (Table 2) can also be used.10
Validated questionnaires that are useful during the review include: generalised anxiety disorder assessment (GAD-7),35 Patient Health Questionnaire-9 (PHQ-9),36 binge eating screening and Epworth sleepiness scale (ESS). Assessing readiness to change and weight related quality of life are also very important.
A complete assessment of obesity requires a skilled multidisciplinary team (MDT), which is the gold standard so that underlying causes, barriers, complications and multiple health conditions can be identified, and specific, measurable, achievable, relevant and time-bound (SMART) goals can be created.
Investigations
Blood tests, including full blood count (FBC), liver function tests, renal function tests, thyroid function tests and a lipid profile should be done at least once. Haemoglobin (Hb) A1C and plasma glucose should be done if the patient has, or is suspected to have, diabetes. The Fibrosis-4 (FIB-4) score is an inexpensive but valuable tool scoring system to rule out advanced liver fibrosis by utilizing FBC, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), but might not be clinically useful in patients with Class 3 obesity.37 Some centres also request uric acid and a bone profile. Nutritional assessment should be done because nutritional deficiencies, such as Vitamin D and folate deficiencies, are very common and will need replacement.
The ESS can be used to assess the risk of OSA, but, in the presence of clinical symptoms, assessment for obesity hypoventilation syndrome/OSA might be warranted. For screening patients who are candidates for bariatric surgery, the STOP-BANG questionnaire is preferable to ESS for OSA.38 Echocardiography should be performed if there are features of heart failure.
Body composition can be accurately measured using bioelectrical impedance, and imaging techniques, such as dual energy X-ray absorptiometry (DEXA),39 but these are not routinely done.
At Barts Health NHS Trust, we use bioelectrical impedance analysis (BIA) equipment to measure patients' muscle, total fat, visceral fat levels and basal metabolic rate. Patients who increase their activity levels can be motivated by seeing their fat percentage decrease and muscle mass increase even if their overall weight does not change. This is especially true of visceral fat levels: even if their overall weight does not change, a reduction in this type of fat will have great health benefits.
The machine also calculates basal metabolic rate (BMR), that is, the amount of energy the body needs for basic functioning. In some people, this can be very low as a result of low muscle mass and high fat mass, implying that a person's energy requirements can be very low. The BMR reading enables the team to calculate a patient's individual daily energy needs more accurately for weight loss, which they usually find very useful.
Other investigations should be targeted at presenting complaints and examination findings.
Referral
The UK response to obesity is structured around tiered management (Tiers 1–4). Tier 1 refers to universal prevention services, Tier 2 offers lifestyle multicomponent weight management, Tier 3 offers specialist multidisciplinary weight management and Tier 4 refers to bariatric surgery.
A comprehensive MDT assessment is an excellent start to a Tier 3 or equivalent programme. This allows each specialist the opportunity to provide their unique assessment within a shared space and facilitate discussion. A shared care plan can then be devised with the patient.
Referral to Tier 3 services22 should be considered if any of the following apply:
Underlying causes of obesity need to be assessed
Conventional treatment is not working
The patient cannot be managed adequately in Tier 2 services
Specialist interventions or surgery is being considered
Communication with other specialists might be needed depending on associated multiple health conditions, and cross-speciality pathways are important to develop.
Precision medicine
The cause, presentation and complications of obesity differ among individuals, and we should consider interpersonal variability. There is a need to move away from the one-size-fits-all approach and consider precision medicine so that people with obesity derive maximum benefit. This exciting and evolving area includes increased information in many fields, such as genetic, epigenetic, metabolic, pharmacologic, biotechnology, nutrition and clinical.40 Phenotyping to identify the obesity subtype appears to be the way forward but can only be done in specialist centres. Hence, timely referral to an obesity service is vital.
Conclusions
In summary, obesity is common and, although a detailed clinical assessment might not always be possible for healthcare professionals who are not obesity specialists, a focused assessment will help timely referral and appropriate management. Obesity assessment should focus on not only anthropometric measurement, but also identifying the cause and effects of abnormal adiposity. For effective assessment, an environment devoid of stigma is essential.
References
- 1.World Health Organization . Obesity and overweight. WHO, 2021. www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed 12 June 2023]. [Google Scholar]
- 2.National Health Service . Statistics on obesity, physical activity and diet, England 2021. https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-obesity-physical-activity-and-diet/england-2021 [Accessed 12 June 2023].
- 3.De Lorenzo A, Romano L, Di Renzo L, et al. Obesity: a preventable, treatable, but relapsing disease. Nutrition 2020;71:110615. [DOI] [PubMed] [Google Scholar]
- 4.Grant B, Sandelson M, Agyemang-Prempeh B, et al. Managing obesity in people with type 2 diabetes. Clin Med 2021;21:e327–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.World Health Organization . Obesity. www.who.int/health-topics/obesity [Accessed 12 June 2023].
- 6.National Institute for Health and Care Excellence . Obesity: how should I confirm if a person is overweight or obese? https://cks.nice.org.uk/topics/obesity/diagnosis/identification-classification/ [Accessed 12 June 2023].
- 7.Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes 2008;32:S56–9. [DOI] [PubMed] [Google Scholar]
- 8.Blüher M. Metabolically healthy obesity. Endocr Rev 2020;41:bnaa004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond) 2015;128:405–10. [DOI] [PubMed] [Google Scholar]
- 10.Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: An EASO Position Statement on a diagnostic term with clinical and scientific implications. Obes Facts 2019;12:131–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Aasheim ET, Aylwin SJB, Radhakrishnan ST, et al. Assessment of obesity beyond body mass index to determine benefit of treatment. Clin Obes 2011;1:77–84. [DOI] [PubMed] [Google Scholar]
- 12.Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond) 2009;33:289–95. [DOI] [PubMed] [Google Scholar]
- 13.Kuk JL, Ardern CI, Church TS, et al. Edmonton Obesity Staging System: association with weight history and mortality risk. Appl Physiol Nutr Metab 2011;36:570–6. [DOI] [PubMed] [Google Scholar]
- 14.Rubino F, Batterham RL, Koch M, et al. Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity. Lancet Diabetes Endocrinol 2023;11:226–8. [DOI] [PubMed] [Google Scholar]
- 15.Sagi-Dain L, Echar M, Paska-Davis N. How to talk with patients about weight? Viewpoints of 1697 individuals with overweight and obesity. Patient Educ Couns 2022;105:497–501. [DOI] [PubMed] [Google Scholar]
- 16.Brown A, Flint SW, Batterham RL. Pervasiveness, impact and implications of weight stigma. EClinicalMedicine 2022;47:101408. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Batterham RL. Weight stigma in healthcare settings is detrimental to health and must be eradicated. Nat Rev Endocrinol 2022;18:387–8. [DOI] [PubMed] [Google Scholar]
- 18.Obesity UK . Obesity: Language Matters. https://static1.squarespace.com/static/5bc74880ab1a6217704d23ca/t/5f232130bc705028ef88bb89/1596137786647/Obesity+Language+Matters+_FINAL.pdf [Accessed 12 June 2023].
- 19.Yearwood L, Masood W. Behavioral approaches to obesity treatment. Treasure Island; StatPearls Publishing, 2022. [PubMed] [Google Scholar]
- 20.Rollnick S, Butler CC, Kinnersley P, et al. Motivational interviewing. BMJ 2010;340:c1900. [DOI] [PubMed] [Google Scholar]
- 21.Rollnick S, Miller W, Butler. Motivational interviewing in healthcare–helping patients change behaviour. New York; The Guilford Press, 2023. [Google Scholar]
- 22.National Institute for Health and Care Excellence . Obesity: identification, assessment and management. www.nice.org.uk/guidance/cg189/chapter/Recommendations#identifying-and-assessing-overweight-obesity-and-central-adiposity [Accessed 12 June 2023]. [PubMed]
- 23.Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 1997;27:325–51. [DOI] [PubMed] [Google Scholar]
- 24.Vandenbroeck IP, Goossens DJ, Clemens M. Tackling obesities: future choices—Obesity System Atlas. London; Government Office for Science, 2007. [Google Scholar]
- 25.van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. Obes Rev 2019;20:795–804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dasgupta B, Chhipa RR. Evolving lessons on the complex role of AMPK in normal physiology and cancer. Trends Pharmacol Sci 2016;37:192–206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Haute Autorité de Santé . Générique obésités de causes rares, 2021. www.has-sante.fr/jcms/p_3280217/fr/generique-obesites-de-causes-rares [Accessed 12 June 2023].
- 28.Dubern B, Mosbah H, Pigeyre M, et al. Rare genetic causes of obesity: diagnosis and management in clinical care. Ann d'Endocrinologie 2022;83:63–72. [DOI] [PubMed] [Google Scholar]
- 29.Palatini P, Asmar R. Cuff challenges in blood pressure measurement. J Clin Hypertens (Greenwich) 2018;20:1100–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018;14:513–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Xue R, Li Q, Geng Y, et al. Abdominal obesity and risk of CVD: a dose–response meta-analysis of thirty-one prospective studies. Br J Nutr 2021;126:1420–30. [DOI] [PubMed] [Google Scholar]
- 32.Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: differences at 5%, 10%, 15%, and Over. Curr Obes Rep 2017;6:187–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Busetto L, Bettini S, Makaronidis J, et al. Mechanisms of weight regain. Eur J Intern Med 2021;93:3–7. [DOI] [PubMed] [Google Scholar]
- 34.Sharma AM. M, M, M & M: a mnemonic for assessing obesity. Obes Rev 2010;11:808–9. [DOI] [PubMed] [Google Scholar]
- 35.Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7. [DOI] [PubMed] [Google Scholar]
- 36.Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med 2001;16:606–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Eren F, Kaya E, Yilmaz Y. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol 2022;34(1):98–103. [DOI] [PubMed] [Google Scholar]
- 38.Kreitinger KY, Lui MMS, Owens RL, et al. Screening for obstructive sleep apnea in a diverse bariatric surgery population. Obesity (Silver Spring) 2020;28:2028–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Ponti F, Plazzi A, Guglielmi G, et al. Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution. BJR Case Rep 2019;5:20170078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hurtado AMD, Acosta A. Precision medicine and obesity. Gastroenterol Clin North Am 2021;50:127–39. [DOI] [PMC free article] [PubMed] [Google Scholar]